Backed by Science

Luminopia™ One is a digital therapeutic developed closely with leading physicians and neuroscientists that has been validated through a series of clinical trials, including a prospective, randomized controlled trial.

Luminopia One has been approved by the FDA for prescription use, and is indicated for improvement in visual acuity in amblyopia patients aged 4-7.

Supporting scientific literature

Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia

Xiao S, Angjeli E, Wu HC, et al. Ophthalmology 2021. In Press.

Digital Therapeutic Improves Visual Acuity and Encourages High Adherence in Amblyopic Children in Open-Label Pilot Study

Xiao S, Gaier ED, Wu HC, et al. Journal of AAPOS 2021;25(2):87.e1-87.e6

Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia

Xiao S, Gaier ED, Mazow ML, et al. Scientific Reports 2020;10:8328.